BFNH BioForce Nanosciences Holdings (PK)

BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micro and nano scales, today announced record revenue and gross profit for the three months ended March 31, 2008. First Quarter Highlights Net revenues were $403,567 for the first quarter of 2008, the highest first quarter revenues in the Company�s history, and a 13% increase from net revenues of $358,755 for the first quarter of 2008. Five Nano eNabler� systems were sold during the first quarter of 2008, equaling the highest number of Nano eNabler� systems sold in any quarter in BioForce�s history. Gross profit was $189,342 for the first quarter of 2008, the highest first quarter gross profit in the Company�s history, and a 7% increase from gross profit of $176,149 for the first quarter of 2007. Net loss on common stock was $756,162 ($0.03 per fully diluted share) for the first quarter of 2008, as compared to a net loss on common stock of $923,317 ($0.04 per fully diluted share) for the first quarter of 2007. Operations Review Kerry Frey, President and Chief Executive Officer of BioForce, said, �We are pleased with what was another excellent quarter for BioForce. We sold five Nano eNabler� systems during the three months ended March 31, 2008, matching the number sold during the fourth quarter of 2007. Two of the sales during the first quarter were to overseas customers, continuing the good results that we have experienced from our international network of distributors. The other three sales were to U.S.-based research institutions that took part in our 2006 Pilot Placement Program. It is encouraging that these long-time Nano eNabler� users have seen fit to purchase their instruments as vital parts of their research direction. �We have now sold sixteen Nano eNabler� systems since the initial sale of the product in 2006, with ten of those sales occurring in the past two quarters. The momentum that we are seeing in the market is certainly encouraging. We believe that the unique capability of the Nano eNabler� to deposit biological materials, such as proteins and antibodies, in one to twenty micron spot sizes in a precise, consistent, flexible and affordable manner will provide expanding demand for this product. The industrial consulting firm of Frost and Sullivan concurred with our views of the advantages of the Nano eNabler� in their February 2008 report describing the key advantages of the Nano eNabler� over other technologies for the deposition of biological materials at the ultramicro and nano scales." Frey concluded, �During the first quarter we announced two new products, our Cyto eNabler� molecular printer, which is specifically configured for the needs of cellular biology researchers, and our custom patterned surfaces, which are produced to the specifications of the customer by our personnel using the Nano eNabler�. We believe that the introduction of these new products, plus the Nano eNabler� system and the continued development of the market for that product, will provide the basis for our future growth.� Greg Brown, BioForce�s Chief Financial Officer, commented, �The growth in our revenues, and reduction in our operating expenses, has allowed us to significantly narrow our operating losses over the past two quarters, and we remain focused upon achieving profitability. While we are pleased with these results and the resulting reduction in our cash loss from operations, we do require additional financing and are in discussions with potential sources of capital.� About BioForce Nanosciences Holdings, Inc. BioForce Nanosciences creates products and solutions for the life sciences by integrating biological and mechanical systems at the micro and nano scales. BioForce�s flagship product, the Nano eNabler� molecular printer, gives the Company and its customers a platform for development and discovery by printing tiny domains of biological materials on surfaces with nanometer spatial precision. BioForce technology is being used in areas such as biosensor functionalization; pattering and cell adhesion; and the printing of proteins to guide neural cell growth. For more information, visit www.bioforcenano.com or call 515-233-8333. This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date. BIOFORCE NANOSCIENCES HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS � � ASSETS 03/31/08 � 12/31/07 (unaudited) CURRENT ASSETS Cash and cash equivalents $ 57,773 $ 268,930 Accounts receivable - trade, net 172,732 313,756 Account receivable - invoice factoring 34,071 - Inventory 900,616 1,046,683 Prepaid expenses and other assets � 90,908 � � 146,007 � Total current assets � 1,256,100 � � 1,775,376 � PROPERTY AND EQUIPMENT � Computer equipment 113,963 113,963 � Scientific and laboratory equipment 906,382 889,368 � Leasehold improvements 380,000 380,000 � Office furniture and fixtures � 89,760 � � 89,760 � Total 1,490,105 1,473,091 � Less accumulated depreciation � 944,470 � � 889,469 � Net property and equipment � 545,635 � � 583,622 � INTANGIBLE ASSETS Patent costs, net of accumulated amortization of $86,201 and $78,502, respectively 678,997 641,017 Trademark costs, net of accumulated amortization of $17,588 and $15,471, respectively � 97,823 � � 90,908 Total intangible assets � 776,821 � � 731,925 � TOTAL ASSETS $ 2,578,556 � $ 3,090,923 BIOFORCE NANOSCIENCES HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS � � LIABILITIES AND STOCKHOLDERS' EQUITY 03/31/08 � 12/31/07 (unaudited) CURRENT LIABILITIES Accounts payable $ 418,431 $ 305,314 Accrued expenses 228,143 241,650 Recourse obligation - invoice factoring 7,962 - Accrued dividends on preferred stock 10,000 13,333 Deferred revenue 35,861 53,754 Current portion of long-term debt � 73,247 � � 89,180 � Total current liabilities 773,644 703,231 � LONG-TERM DEBT, NET � 143,607 � � 154,860 � Total liabilities � 917,251 � � 858,091 COMMITMENTS and CONTINGENCIES � STOCKHOLDERS' EQUITY Preferred stock - 2008 and 2007: $0.001 par value, 10,000,000 shares authorized to be issued in various classes Series A Convertible Preferred Stock - $0.001 par value, 2007: 1,100,000 shares authorized, 1,000,000 shares issued and outstanding, 2008: liquidation � value $510,000; 2007: liquidation value $513,333 1,000 1,000 � Common stock - 2008 and 2007: $0.001 par value, 100,000,000 shares authorized, 2008: 25,116,401 shares issued and outstanding; 2007: 25,099,950 shares � issued and outstanding 25,116 25,100 � Additional paid-in capital 16,531,333 16,341,714 Deferred stock offering costs (5,000) - � Accumulated deficit � (14,891,144) � � (14,134,982) � Total stockholders' equity � 1,661,305 � � 2,232,832 � TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 2,578,556 � $ 3,090,923 - more - BIOFORCE NANOSCIENCES HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) � � For the Three Months Ended March 31, 2008 � 2007 REVENUES $ 403,567 $ 358,755 � COST OF GOODS SOLD � 214,225 � � 182,606 � Gross profit 189,342 176,149 � OPERATING EXPENSES Research and development 298,490 278,800 Sales and marketing 289,695 306,008 General and administrative 442,975 658,708 Reimbursement of grant expenses � (99,895) � � (124,923) Total operating expenses � 931,265 � � 1,118,593 � Loss from operations before other income (expense) (741,923) (942,444) � OTHER INCOME (EXPENSE) Interest and other income 1,540 22,136 Interest expense � (5,779) � � (3,009) Total other income (expense) � (4,239) � � 19,127 � Loss before income tax (746,162) (923,317) � INCOME TAX EXPENSE � - � � - � Net loss $ (746,162) $ (923,317) � DIVIDENDS ON PREFERRED STOCK � 10,000 � � - � Net loss on common stock $ (756,162) � $ (923,317) � BASIC AND DILUTED LOSS PER SHARE $ (0.03) � $ (0.04) � WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING � 25,114,051 � � 24,040,950